Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics

01-11-2001 | Current Opinion

Pharmacogenetics

The Therapeutic Drug Monitoring of the Future?

Authors: Mary H. H. Ensom, Thomas K. H. Chang, Payal Patel

Published in: Clinical Pharmacokinetics | Issue 11/2001

Login to get access

Abstract

Genetic variability in drug response occurs as a result of molecular alterations at the level of drug-metabolising enzymes, drug targets/receptors, and drug transport proteins. In this paper, we discuss the possibility that therapeutic drug monitoring (TDM) in the future will involve not the mere measurement and interpretation of drug concentrations but will include both traditional TDM and pharmacogenetics-oriented TDM.
In contrast to traditional TDM, which cannot be performed until after a drug is administered to the patient, pharmacogenetics-oriented TDM can be conducted even before treatment begins. Other advantages of genotyping over traditional TDM include, but are not limited to, the following: (i) it does not require the assumption of steady-state conditions (or patient compliance) for the interpretation of results; (ii) it can often be performed less invasively (with saliva, hair root or buccal swab samples); (iii) it can provide predictive value for multiple drugs [e.g. a number of cytochrome P450 (CYP) 2D6, CYP2C19 or CYP2C9 substrates] rather than a single drug; (iv) it provides mechanistic, instead of merely descriptive, information; and (v) it is constant over an individual’s lifetime (and not influenced by concurrent drug administration, alteration in hormonal levels or disease states). Pharmacogenetic information can be applied a priori for initial dose stratification and identification of cases where certain drugs are simply not effective. However, traditional TDM will still be required for all of the reasons that we use it now.
In current clinical practice, pharmacogenetic testing is performed for only a few drugs (e.g. mercaptopurine, thioguanine, azathioprine, trastuzumab and tacrine) and in a limited number of teaching hospitals and specialist academic centres. We propose that other drugs (e.g. warfarin, phenytoin, codeine, oral hypoglycaemics, tricyclic antidepressants, aminoglycosides, digoxin, cyclosporin, cyclophosphamide, ifosfamide, theophylline and clozapine) are potential candidates for pharmacogenetics-oriented TDM. However, prospective studies of pharmacogenetics-oriented TDM must be performed to determine its efficacy and cost effectiveness in optimising therapeutic effects while minimising toxicity
In the future, in addition to targeting a patient’s drug concentrations within a therapeutic range, pharmacists are likely to be making dosage recommendations for individual drugs on the basis of the individual patient’s genotype. As we enter the era of personalised drug therapy, we will be able to identify not only the best drug to be administered to a particular patient, but also the most effective and safest dosage from the outset of therapy.
Literature
1.
Ensom MHH, Davis GA, Cropp CD, et al. Clinical pharmacokinetics in the 21st century: does the evidence support definitive outcomes? Clin Pharmacokinet 1998; 34: 265–79PubMedCrossRef
2.
Hepler CD, Strand LH. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990; 47: 533–43PubMed
3.
Burton ME, Brater C, Chen PS, et al. A Bayesian feedback method of aminoglycoside dosing. Clin Pharmacol Ther 1985; 37: 349–57PubMedCrossRef
4.
Vozeh S, Kewitz G, Perruchoud A, et al. Theophylline serum concentration and therapeutic effect in severe acute bronchial obstruction: the optimal use of intravenously administered theophylline. Am Rev Respir Dis 1982; 125: 181–4PubMed
5.
Vozeh S, Uematsu T, Schmidlin O, et al. Computer-assisted individualized lidocaine dosage: clinical evaluation and comparison with physician performance. Am Heart J 1987; 113: 928–33PubMedCrossRef
6.
Beardsley RS, Freeman JM, Appel FA. Anticonvulsant serum levels are useful only if the physician appropriately uses them: an assessment of the impact of providing serum level data to physicians. Epilepsia 1983; 24: 330–5PubMedCrossRef
7.
Whiting B, Kelman AW, Bryson SM, et al. Clinical pharmacokinetics: a comprehensive system for therapeutic drug monitoring and prescribing. BMJ 1984; 288: 543–5CrossRef
8.
Mungall D, Marshall J, Penn D, et al. Individualized theophylline therapy: the impact of clinical pharmacokinetics on patient outcomes. Ther Drug Monit 1983; 5: 95–101PubMedCrossRef
9.
Donahue T, Dotter J, Alexander G, et al. Pharmacist based iv theophylline therapy. Hosp Pharm 1989; 24: 442–60
10.
Hurley SF, Dziukas LJ, McNeill JJ, et al. A randomized controlled clinical trial of pharmacokinetic theophylline dosing. Am Rev Respir Dis 1986; 134: 1219–24PubMed
11.
Winter ME, Herfindal ET, Bernstein LR. Impact of decentralized pharmacokinetics consultation service. Am J Hosp Pharm 1986; 43: 2178–84PubMed
12.
Franson TR, Quebbeman EJ, Whipple J. Prospective comparison of traditional and pharmacokinetic aminoglycoside dosing methods. Crit Care Med 1988; 16: 840–3PubMedCrossRef
13.
Hoffa DE. Serial pharmacokinetic dosing of aminoglycosides: a community hospital experience. Ther Drug Monit 1989; 11: 574–9PubMedCrossRef
14.
Destache CJ, Meyer SK, Padomek MT. Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides for gram-negative infections. Drug Intell Clin Pharm 1989; 23: 33–8
15.
Horn JR, Christensen DB, de Blaquiere PA. Evaluation of a digoxin pharmacokinetic monitoring service in a community hospital. Drug Intell Clin Pharm 1985; 19: 45–52PubMed
16.
Ho KKL, Thiessen JJ, Bryson SM, et al. Challenges in comparing treatment outcome from a prospective with that of a retrospective study: assessing the merit of gentamicin therapeutic drug monitoring in pEdiatric oncology. Ther Drug Monit 1994; 16: 238–47PubMedCrossRef
17.
Bollish SJ, Kelly WN, Miller DE, et al. Establishing an aminoglycoside pharmacokinetic monitoring service in a community hospital. Am J Hosp Pharm 1981; 38: 73–6PubMed
18.
Michalko KJ, Blain L. An evaluation of a clinical pharmacokinetic service for serum digoxin levels. Ther Drug Monit 1987; 9: 311–9PubMedCrossRef
19.
Wing DS, Duff HJ. Evaluation of a therapeutic drug monitoring program for theophylline in a teaching hospital. Drug Intell Clin Pharm 1987; 21: 702–6PubMed
20.
Job ML, Ward ES, Murphy JE. Seven years of experience with a pharmacokinetic service. Hosp Pharm 1989; 24: 512–9, 526PubMed
21.
McLean W, Lalonde R, Roy M. The history of a comprehensive pharmacokinetic service. Can J Hosp Pharm 1989; 42: 223–8PubMed
22.
Ried LD, McKenna DA, Horn JR. Meta-analysis of research on the effect of clinical pharmacokinetics services on therapeutic drug monitoring. Am J Hosp Pharm 1989; 46: 945–51PubMed
23.
Wing DS, Duff HJ. The impact of a therapeutic drug monitoring program for phenytoin. Ther Drug Monit 1989; 11: 32–7PubMedCrossRef
24.
Dager WE, Albertson TE. Impact of therapeutic drug monitoring of intravenous theophylline regimens on serum theophylline concentrations in the medical intensive care unit. Ann Pharmacother 1992; 26: 1287–91PubMed
25.
Schloemer JH, Zagozen JJ. Cost analysis of an aminoglycoside pharmacokinetic dosing program. Am J Hosp Pharm 1984; 41: 2347–51PubMed
26.
McCormack JP, Lynd LD, Pfeifer NM. Vancomycin cost containment through a therapeutic and pharmacokinetic drug monitoring service. Can J Hosp Pharm 1989; 42: 3–9
27.
Bootman JL, Wertheimer AI, Zaske D, et al. Individualizing gentamicin dosage regimens in burn patients with gram-negative septicemia: a cost-benefit analysis. J Pharm Sci 1979; 68: 267–72PubMedCrossRef
28.
Zaske DE, Bootman JL, Solem LB, et al. Increased burn patient survival with individualized dosages of gentamicin. Surgery 1982; 91: 142–9PubMed
29.
Sveska KJ, Roffe BD, Solomon DK, et al. Outcome of patients treated by an aminoglycoside pharmacokinetic dosing service. Am J Hosp Pharm 1985; 42: 2472–8PubMed
30.
Crist KD, Nahata MC, Ety J. Positive impact of a therapeutic drug-monitoring program on total aminoglycoside dose and cost of hospitalization. Ther Drug Monit 1987; 9: 306–10PubMedCrossRef
31.
Destache CJ, Meyer SK, Bittner MJ, et al. Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides: a cost-benefit analysis. Ther Drug Monit 1990; 12: 419–26PubMedCrossRef
32.
Destache CJ, Meyer SK, Rowley KM. Does accepting pharmacokinetic recommendations impact hospitalization?: a cost-benefit analysis. Ther Drug Monit 1990; 12: 427–33PubMedCrossRef
33.
Whipple JK, Ausman RK, Franson T, et al. Effect of individualized pharmacokinetic dosing on patient outcome. Crit Care Med 1991; 19: 1480–5PubMedCrossRef
34.
Burton ME, Ash CL, Hill DP, et al. A controlled trial of the cost benefit of computerized Bayesian aminoglycoside administration. Clin Pharmacol Ther 1991; 49: 685–94PubMedCrossRef
35.
Ioannides-Demos LL, Horne MK, Tong N, et al. Impact of a pharmacokinetics consultation service on clinical outcomes in an ambulatory-care epilepsy clinic. Am J Hosp Pharm 1988; 45: 1549–51PubMed
36.
Botha J, Bobat RA, Moosa A, et al. Therapeutic drug monitoring in a paediatric epilepsy clinic. S Afr Med J 1990; 77: 511–4PubMed
37.
McFayden ML, Miller R, Juta M, et al. The relevance of a first-world therapeutic drug monitoring service to the treatment of epilepsy in third-world conditions. S Afr Med J 1990; 78: 587–90
38.
Duhme DW, Greenblatt DJ, Koch-Weser J. Reduction of digoxin toxicity associated with measurement of serum levels. Ann Intern Med 1974; 80: 516–9PubMed
39.
Welty TE, Copa AK. Impact of vancomycin therapeutic drug monitoring on patient care. Ann Pharmacother 1994; 28: 1335–9PubMed
40.
del Mar Fernandez de Gatta M, Calvo V, Hernandez JM, et al. Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies. Clin Pharmacol Ther 1996; 60: 332–40CrossRef
41.
Kimelblatt BJ, Bradbury K, Chodoff L, et al. Cost-benefit analysis of an aminoglycoside monitoring service. Am J Hosp Pharm 1986; 43: 1205–9PubMed
42.
Smith M, Murphy JE, Job ML, et al. Aminoglycoside monitoring: use of a pharmacokinetic service versus physician recommendations. Hosp Formul 1987; 22: 92–102PubMed
43.
Dillion KR, Dougherty SH, Casner P, et al. Individualized pharmacokinetic versus standard dosing of amikacin: a comparison of therapeutic outcomes. J Antimicrob Chemother 1989; 24: 581–9CrossRef
44.
Pinilla J, Shafran S, Conly J. A utilization and cost-benefit analysis of an aminoglycoside kinetics monitoring service. Clin Invest Med 1992; 15: 8–17PubMed
45.
Leehey DJ, Braun BI, Tholl DA, et al. Can pharmacokinetic dosing decrease nephrotoxicity associated with aminoglycoside therapy? J Am Soc Nephrol 1993; 4: 81–90PubMed
46.
Lehmann CR, Leonard RG. Effect of theophylline pharmacokinetic monitoring service on cost and quality of care. Am J Hosp Pharm 1982; 39: 1656–62PubMed
47.
Casner PR, Reilly R, Ho H. A randomized controlled trial of computerized pharmacokinetic theophylline dosing versus empiric physician dosing. Clin Pharmacol Ther 1993; 53: 684–90PubMedCrossRef
48.
Hess P, Cooper D. Impact of pharmacogenomics on the clinical laboratory. Mol Diagn 1999; 4: 289–98PubMedCrossRef
49.
Jaggers LD. Pharmacogenomics: worthy of pharmacy’s attention. Am J Health-Syst Pharm 1999; 56: 27PubMed
50.
Regalado A. Inventing the pharmacogenomics business. Am J Health Syst Pharm 1999; 56: 40–50PubMed
51.
Nebert DW. Pharmacogenetics and pharmacogenomics: why is this relevant to the clinic. Clin Genet 1999; 56: 247–58PubMedCrossRef
52.
Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487–91PubMedCrossRef
53.
Carrico JM. Human Genome Project and pharmacogenomics: implications for pharmacy. J Am Pharm Assoc 2000; 40: 115–6
54.
55.
56.
57.
Mancinelli L, Cronin M, Sadee W Pharmacogenomics: the promise of personalized medicine. AAPS PharmSci 2000; 2: 30–7
58.
Rioux PP. Clinical trials in pharmacogenetics and pharmacogenomics: methods and applications. Am J Health Syst Pharm 2000; 57: 887–901PubMed
59.
60.
Ferrari P. Pharmacogenomics: a new approach to individual therapy of hypertension? Curr Opin Nephrol Hypertens 1998; 7: 217–22PubMedCrossRef
61.
62.
Spear BB. Pharmacogenomics: today, tomorrow, and beyond. Drug Benefit Trends 1999; 11: 53–4
63.
Cantor CR. Pharmacogenetics becomes pharmacogenomics: wake up and get ready. Mol Diagn 1999; 4: 287–8PubMedCrossRef
64.
Langevin BC. Pharmacogenomics: tailoring drug therapy. J Am Pharm Assoc 1999; 39: 597–8
65.
Grant DM. Pharmacogenomics and the changingface of clinical pharmacology. Can J Clin Pharmacol 1999; 6: 131–2PubMed
66.
Shi MM, Bleavins MR, de la Iglesia FA. Technologies for detecting genetic polymorphisms in pharmacogenomics. Mol Diagn 1999; 4: 343–51PubMedCrossRef
67.
Carsen PE, Flanagan CL, Iokes CE, et al. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science 1956; 124: 484–5CrossRef
68.
Hughes HB, Biehl JP, Jones AP, et al. Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. Am Rev Tuberculosis 1954; 70: 266–73
69.
Vogel F. Moderne probleme der humangenetik. Ergeb Inn Med Kinderheilkd 1959; 12: 52–125CrossRef
70.
Collins FS. Shattuck lecture — medical and societal consequences of the Human Genome Project. N Engl J Med 1999; 341: 28–37PubMedCrossRef
71.
Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001; 291: 1304–51PubMedCrossRef
72.
Spurr N, Darvasi A, Terrett J, et al. New technologies and DNA resources for high throughput biology. Br Med Bull 1999; 55: 309–24PubMedCrossRef
73.
De Benedetti VM, Biglia N, Sismondi P, et al. DNA chips: the future of biomarkers. Int J Biol Markers 2000; 15: 1–9PubMed
74.
Ghosh D. High throughput and global approaches to gene expression. Comb Chem High Throughput Screen 2000; 3: 411–20PubMedCrossRef
75.
Holland RW, Nimmo CM. Transitions: part 1. Beyond pharmaceutical care. Am J Health Syst Pharm 1999; 56: 1758–64PubMed
76.
Brockmoller J, Kirchheiner J, Meisel C, et al. Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. Pharmacogenomics 2000; 1: 125–51PubMedCrossRef
77.
Zurlinden J. Pharmacogenomics: tailoring the drug to the patient. Nurs Spectr 1998; 8: 10,24
78.
Radomski KM, Bush BA, Ensom MHH. Collaboration between pharmacy and laboratory: defining total allowable error limits for therapeutically monitored drugs. Ann Pharmacother 1998; 32: 170–5PubMedCrossRef
79.
80.
Chen S, Wedlund PJ. Correlation between cytochrome P-450 CYP2D6 (CYP2D6) genotype and phenotype. Acta Pharmacol Sin 1999; 20: 586–8
81.
Poolsup N, Po ALW, Knight TL. Pharmacogenetics and psychopharmacotherapy. J Clin Pharm Ther 2000; 25: 197–220PubMedCrossRef
82.
Mitchell PB. Therapeutic drug monitoring of psychotropic medications. Br J Clin Pharmacol 2000; 49: 303–12PubMedCrossRef
83.
Chen S, Chou WH, Blouin RA, et al. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 1996; 60: 522–34PubMedCrossRef
84.
Bork JA, Rogers T, Wedlund PJ, et al. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. J Clin Psychiatry 1999; 60: 469–76PubMedCrossRef
85.
Rasmussen BB, Brosen K. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit 2000; 22: 143–54PubMedCrossRef
86.
Mahgoub A, Idle JR, Dring LG, et al. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 2: 584–6PubMedCrossRef
87.
Distlerath LM, Reilly PEB, Martin MV, et al. Purification and characterization of the human liver cytochrome P-450 involved in debrisoquine 4-hydroxylation and phenacetin Odeethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1985; 260: 9057–67PubMed
88.
Gillam EMJ, Guo Z, Martin MV, et al. Expression of cytochrome P450 2D6 in Escherichia coli, purification, and spectral and catalytic characterization. Arch Biochem Biophys 1995; 319: 540–50PubMedCrossRef
89.
Fromm MF, Kroemer HK, Eichelbaum M. Impact of P450 genetic polymorphism on the first-pass extraction of cardiovascular and neuroactive drugs. Adv Drug Deliv Rev 1997; 27: 171–99PubMedCrossRef
90.
91.
Alfaro CL, Lam YWF, Simpson J, et al. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J Clin Pharmacol 2000; 40: 58–66PubMedCrossRef
92.
Goldstein JA, Faletto MB, Romkes-Sparks M, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994; 33: 1743–52PubMedCrossRef
93.
94.
de Morais SM, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269: 15419–22PubMed
95.
de Morais SM, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46: 594–8PubMed
96.
Aoyama N, Tanigawara Y, Kita T, et al. Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helibactor pylori eradication in cytochrome P450 2C19 poor metabolizers. J Gastroenterol 1999; 34 Suppl. 11: 80–3PubMed
97.
Tanigawara Y, Aoyama N, Kita T, et al. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clin Pharmacol Ther 1999; 66: 528–34PubMedCrossRef
98.
Furuta T, Ohashi K, Kosuge K, et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 1999; 65: 552–61PubMedCrossRef
99.
Furuta T, Ohashi K, Kamata T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998; 129: 1027–30PubMed
100.
Sagar M, Seensalu R, Tybring G, et al. CYP2C19 genotype and phenotype determined with omeprazole in patients with acid-related disorders with and without Helicobacter pylori infection. Scand J Gastroenterol 1998; 33: 1034–8PubMedCrossRef
101.
Miners JO, Birkett DJ. Cytochrome P450 2C9: an enzyme of major importance in human drug metablism. Br J Clin Pharmacol 1998; 45: 525–38PubMedCrossRef
102.
Veronese ME, Doecke CJ, MacKenzie PI, et al. Site-directed mutation studies of human liver cytochrome P450 isoenzymes in the CYP2C subfamily. Biochem J 1993; 289: 533–8PubMed
103.
Sullivan-Klose TH, Ghanayem BI, Bell DA, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 6: 341–9PubMedCrossRef
104.
Chang TKH, Yu L, Goldstein JA, et al. Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-Ile359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics 1997; 7: 211–21PubMedCrossRef
105.
Wang Q, Shen J, Splawski I, et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 1995; 80: 805–11PubMedCrossRef
106.
Stubbins MJ, Harries LW, Smith G, et al. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 1996; 6: 429–39PubMedCrossRef
107.
Nasu K, Kubota T, Ishizaki T. Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics 1997; 7: 405–9PubMedCrossRef
108.
Bhasker CR, Miners JO, Coulter S, et al. Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics 1997; 7: 51–8PubMedCrossRef
109.
London SJ, Sullivan-Klose T, Daly AK, et al. Lung cancer risk in relation to the CYP2C9 genetic polymorphism among Caucasians in Los Angeles county. Pharmacogenetics 1997; 7: 401–4PubMedCrossRef
110.
Aynacioglu AS, Brockmoller J, Bauer S, et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 1999; 48: 409–15PubMedCrossRef
111.
Aithal GP, Day CP, Leathart JBS, et al. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics 2000; 10: 511–8PubMedCrossRef
112.
Takanashi K, Tainaka H, Kobayashi K, et al. CYP2C9 Ile359and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 2000; 10: 95–104PubMedCrossRef
113.
Zilly W. Breimer DD, Richter E. Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance. Eur J Clin Pharmacol 1975; 9: 219–27PubMedCrossRef
114.
Grant DM, Goodfellow GH, Sugamori KS, et al. Pharmacogenetics of the human arylamine N-acetyltransferases. Pharmacology 2000; 61: 204–11PubMedCrossRef
115.
Krynetski EY, Evans WE. Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanisms and clinical importance. Pharmacology 2000; 61: 136–46PubMedCrossRef
116.
Grant DM, Hughes NC, Janezic SA, et al. Human acetyl-transferase polymorphisms. Mutat Res 1997; 376: 61–70PubMedCrossRef
117.
Spielberg SP. N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism. J Phar-macokinet Biopharm 1996; 24: 509–19
118.
Nakamura H, Uetrecht J, Cribb AE, et al. In vitro formation, disposition and toxicity of N-acetoxy-sulfamethoxazole, a potential mediator of sulfamethoxazole toxicity. J Pharmacol Exp Ther 1995; 274: 1099–104PubMed
119.
Blum M, Demierre A, Grant DM, et al. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci U S A 1991; 88: 5237–41PubMedCrossRef
120.
Martinez FD, Graves PE, Baldini M, et al. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997; 100: 3184–8PubMedCrossRef
121.
122.
Schinkel AH. The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 1997; 8: 161–70PubMedCrossRef
123.
Mickley LA, Lee JS, Weng Z. Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood 1998; 91: 1749–56PubMed
124.
Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical, cellular and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39: 361–89PubMedCrossRef
125.
Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci 2000; 97: 3473–8PubMedCrossRef
126.
Krynetski EY, Evans WE. Pharmacogenetics of cancer therapy: getting personal. Am J Hum Genet 1998; 63: 11–6PubMedCrossRef
127.
Tai H, Krynetski EY, Yates CR, et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 1996; 58: 694–702PubMed
128.
Goldenberg MM. Trastuzumab, a recombinant DNA derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999; 21: 309–18PubMedCrossRef
129.
Baselge J, Norton L, Albaneil J, et al. Recombinant humanized anti-HER2 antibody (HERCEPTIN) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998; 58: 2825–31
130.
Pharmacogenomicsatwork [letter]. Nat Biotechnol 1998; 16: 885
131.
132.
Farlow MR, Lahiri DK, Poirier J, et al. Apolipoprotein E genotype and gender influence response to tacrine therapy. Ann NY Acad Sci 1996; 802: 101–10PubMedCrossRef
133.
Meyer UA. Pharmacogenetics. In: Carruthers SG, Hoffman BB, Melmon KL, et al., editors. Melmon and Morrelli’ clinical pharmacology: basic principles in therapeutics. 4th ed. New York (NY): McGraw-Hill, 2000
134.
Fihn SD, Callahan CM, Martin DC, et al. The risk and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med 1996; 124: 970–9PubMed
135.
James AH, Britt RP, Raskino CL, et al. Factors affecting the maintenance dose of warfarin. J Clin Pathol 1992; 45: 704–6PubMedCrossRef
136.
Hallak HO, Wedlund PJ, Modi MW, et al. High clearance of (S)-warfarin in a warfarin resistant subject. Br J Clin Pharmacol 1993; 35: 327–30PubMedCrossRef
137.
Rettie AE, Korzekwa KR, Kunze KL, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-450 2C9 in the etiology of (S)-warfarin-drug interaction. Chem Res Toxicol 1992; 5: 54–9PubMedCrossRef
138.
Rettie AE, Wienkers LC, Gonzalez FJ, et al. Impaired S-warfarin metabolism catalyzed by R144C allelic variant of CYP2C9. Pharmacogenetics 1994; 4: 39–42PubMedCrossRef
139.
Haining RL, Hunter AP, Veronese ME, et al. Allelic variants of human cytochrome P-150 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys 1996; 333: 447–58PubMedCrossRef
140.
Yamazaki H, Inoue K, Shimada T. Roles of two allelic variants (Argl44Cys and Ile359Leu) of cytochrome P450 2C9 in the oxidation of tolbutamide and warfarin by human liver microsomes. Xenobiotica 1998; 28: 103–15PubMedCrossRef
141.
Yamazaki H, Inoue K, Chiba K, et al. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprogen, and diclofenac by human liver microsomes. Biochem Pharmacol 1998; 56: 243–51PubMedCrossRef
142.
Takahashi H, Kashima T, Nomoto S, et al. Comparison between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics 1998; 8: 365–73PubMedCrossRef
143.
Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717–9PubMedCrossRef
144.
Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000; 96: 1816–9PubMed
145.
Ieiri I, Mamiya K, Urae A, et al. Stereoselective 4′-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese. Br J Clin Pharmacol 1997; 43: 441–5PubMedCrossRef
146.
Bajpal M, Roskos LK, Shen DD, et al. Roles of cytochrome P450 2C9 and cytochrome P450 2C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos 1996; 24: 1401–3
147.
Kutt H, Wolk M, Scherman R, et al. Insufficient parahydroxylation as a cause of diphenylhydantoin toxicity. Neurology 1964; 14: 542–8PubMedCrossRef
148.
Andreasen PB, Froland A, Skovsted L, et al. Diphenylhydantoin half-life in man and its inhibition by phenylbutazone: the role of genetic factors. Acta Med Scand. 1973; 193: 561–4PubMedCrossRef
149.
Vasko MR, Bell RD, Daly DD, et al. Inheritance of phenytoin hypometabolism: a kinetic study of one family. Clin Pharmacol Ther 1980; 27: 96–103PubMedCrossRef
150.
Vermeij P, Ferrari MD, Buruma OJ, et al. Inheritance of poor phenytoin parahydroxylation capacity in a Dutch family. Clin Pharmacol Ther 1988; 44: 588–93PubMedCrossRef
151.
Hormans Y, Van Den Berge V, Bouckaert A, et al. Phenytoin hydroxylation in a healthy Caucasian population: bimodal distribution of hydroxyphenytoin urinary excretion. Pharmacol Toxicol 1997; 81: 276–9
152.
Odani A, Hasimoto Y, Otsuki Y, et al. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin Pharmacol Ther 1997; 62: 287–92PubMedCrossRef
153.
Mamiya K, Ieiri I, Shimamoto J, et al. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia 1998; 39: 1317–23PubMedCrossRef
154.
Ninomiya H, Mamiya K, Matsuo S, et al. Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication. Ther Drug Monit 2000; 22: 230–2PubMedCrossRef
155.
Ieiri I, Tainaka H, Morita T, et al. Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis. Ther Drug Monit 2000; 22: 237–44PubMedCrossRef
156.
Imai J, Ieiri I, Mamiya K, et al. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. Pharmacogenetics 2000; 10: 85–9PubMedCrossRef
157.
Pert CB, Snyder SH. Properties of opiate-receptor binding in rat brain. Proc Natl Acad Sci U S A 1973; 70: 2243–7PubMedCrossRef
158.
Chen ZR, Somogyi AA, Bochner F. Polymorphic O-demethylation of codeine. Lancet 1988; II: 914–5CrossRef
159.
Dayer P, Desmeules J, Leemann T, et al. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydrox-ylation (cytochrome P-450 dbl/buf1). Biochem Biophys Res Commun 1988: 6
160.
Yue QY, Svensson JO, Alm C, et al. Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation. Br J Clin Pharmacol 1989; 28: 639–45PubMedCrossRef
161.
Johansson I, Yue QY, Dahl ML, et al. Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. Eur J Clin Pharmacol 1991; 40: 553–6PubMed
162.
Poulsen L, Brosen K, Arendt-Nielsen L, et al. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol 1996; 51: 289–95PubMedCrossRef
163.
Caraco Y, Sheller J, Wood AJ. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions. J Pharmacol Exp Ther 1996; 278: 1165–74PubMed
164.
Mikus G, Trausch B, Rodewald C, et al. Effect of codeine on gastroinestinal motility in relation to CYP2D6 phenotype. Clin Pharmacol Ther 1997; 61: 459–66PubMedCrossRef
165.
Eckhardt K, Li S, Ammon S, et al. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain 1998; 76: 27–33PubMedCrossRef
166.
Dalen P, Frengell C, Dahl ML, et al. Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. Ther Drug Monit 1997; 19: 543–4PubMedCrossRef
167.
Brian WR, Srivastava PK, Umbenhauer DR, et al. Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Biochemistry 1989; 28: 4993–9PubMedCrossRef
168.
Wester MR, Lasker JM, Johnson EF, et al. CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes. Drug Metab Dispos 2000; 28: 354–9PubMed
169.
Scott J, Poffenbarger PL. Pharmacogenetics of tolbutamide metabolism in humans. Diabetes 1979; 28: 41–51PubMedCrossRef
170.
Heikinheimo R. Severe prolonged hypoglycemia following tolbutamide and carbutamide treatment. Diabetes 1965; 14: 606–8PubMed
171.
Hansen T, Echwald SM, Hansen L, et al. Decreased tolbutamide-stimulated insulin secretion in healthy subjects with sequence variants in the high-affinity sulfonylurea receptor gene. Diabetes 1998; 47: 598–605PubMedCrossRef
172.
Kidd RS, Straughn AB, Meyer MC, et al. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics 1999; 9: 71–80PubMedCrossRef
173.
Cohen LJ, DeVane CL. Clinical implications of antidepressant pharmacokinetics and pharmacogenetics. Ann Pharmacother 1996; 30: 1471–80PubMed
174.
Dalen P, Dahl ML, Ruiz MRB, et al. 10-hydroxylation of nortriptyline in white persons with 0, 1,2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 1998; 63: 444–52PubMedCrossRef
175.
Yue QY, Zhong ZH, Tybring G, et al. Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 1998; 64: 384–90PubMedCrossRef
176.
Balant-Goriga AE, Balant LP, Garrone G. High blood concentrations of imipramine or clomipramine and therapeutic failure: a case report using drug monitoring data. Ther Drug Monit 1989; 11: 415–20
177.
Bertilsson L, Aberg-Wistedt A, Gustafsson LL, et al. Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther Drug Monit 1985; 7: 478–80PubMedCrossRef
178.
Bertilsson L, Dahl ML, Sjoqvist F, et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine [letter]. Lancet 1993; 341: 63PubMedCrossRef
179.
Meyer UA, Amrein R, Balant LP, et al. Antidepressants and drug-metabolizing enzymes: expert group report. Acta PsychiatrScand 1996; 93: 71–9CrossRef
180.
Prezant TR, Agapian JV, Bohlman MC, et al. Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness. Nat Genet 1993; 4: 289–4PubMedCrossRef
181.
Bacino C, Prezant TR, Bu X, et al. Susceptibility mutations in the mitochondrial small ribosomal RNA gene in aminoglycoside induced deafness. Pharmacogenetics 1995; 5: 165–72PubMedCrossRef
182.
Fischel-Ghodsian N, Prezant TR, Chaltraw WE, et al. Mitochondrial gene mutation is a significant predisposing factor in aminoglycoside ototoxicity. Am J Otolaryngol 1997; 18: 173–8PubMedCrossRef
183.
de Lannoy IA, Silverman M. The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem Biophys Res Commun 1992; 189: 551–7PubMedCrossRef
184.
Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci US 2000; 97: 3473–8CrossRef
185.
Saeki T, Ueda K, Tanigawara Y, et al. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268: 6077–80PubMed
186.
Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988; 43: 630–5PubMedCrossRef
187.
Rivory LP, Qin H, Clarke SJ, et al. Frequency of cytochrome P450 3A4 variant genotype in transplant population and lack of association with cyclosporin clearance. Eur J Clin Pharmacol 2000; 56: 395–8PubMedCrossRef
188.
Ha HR, Chen J, Freiburghaus AU, et al. Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br J Clin Pharmacol 1995; 39: 321–6PubMedCrossRef
189.
Huang JD, Guo WC, Lai MD, et al. Detection of a novel cytochrome P-450 1A2 polymorphism (F21L) in Chinese. Drug Metab Dispos 1999; 27: 98–101PubMed
190.
Sachse C, Brockmoller J, Bauer S, et al. Functional significance of a C→A polymorphism in intron I of the cytochrome P450 CYPlA2gene tested with caffeine. Br J Clin Pharmacol 1999; 47: 445–9PubMedCrossRef
191.
Elermann B, Engel G, Johanson I, et al. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 1997; 44: 439–46CrossRef
192.
Masellis M, Basile VS, Ozdemir V, et al. Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine. Biol Psychiatry 2000; 47: 252–66PubMedCrossRef
193.
Arranz MJ, Munro J, Birkett J, et al. Pharmacogenetic prediction of clozapine response. Lancet 2000; 355: 1615–6PubMedCrossRef
194.
Creinin MD, Lisman R, Strickler RC. Screening for factor V Leiden mutation before prescribing combination oral contraceptives. Fertil Steril 1999; 73: 646–51CrossRef
195.
De Leon J, Barnhill J, Rogers T, et al. Pilot study of the cytochrome P450-2D6 genotype in a psychiatric state hospital. Am J Psychiatry 1998; 155: 1278–80PubMed
196.
Chou WH, Yan FX, de Leon J, et al. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol 2000; 20: 246–51PubMedCrossRef
197.
Wolf CR, Smith G, Smith RL. Science, medicine, and the future: pharmacogenetics. BMJ 2000; 320: 987–90PubMedCrossRef
198.
Ensom MHH. 2001: a pharmacogenomics Odyssey. Can J Hosp Pharm 2001; 54: 6–7
199.
Van Dyke DC, Ellingrod VL, Berg MJ, et al. Pharmacogenetic screening for susceptibility to fetal malformations in women. Ann Pharmacother 2000; 34: 639–45PubMedCrossRef
Metadata
Title
Pharmacogenetics
The Therapeutic Drug Monitoring of the Future?
Authors
Mary H. H. Ensom
Thomas K. H. Chang
Payal Patel
Publication date
01-11-2001
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 11/2001
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.2165/00003088-200140110-00001